blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3487522

EP3487522 - ANTI-CD47 COMBINATION THERAPY [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  13.05.2022
Database last updated on 14.06.2024
FormerRequest for examination was made
Status updated on  26.04.2019
FormerThe international publication has been made
Status updated on  26.01.2018
Most recent event   Tooltip21.07.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Teva Pharmaceuticals Australia Pty Ltd
Level 2
37 Epping Road
Macquarie Park, NSW 2113 / AU
[2019/22]
Inventor(s)01 / POGUE, Sarah Lee
c/- 610 Galveston Drive
Redwood City CA 94063 / US
02 / WILSON, David Scofiled Jr
c/- 610 Galveston Drive
Redwood City CA 94063 / US
03 / TAURA, Tetsuya
c/- 610 Galveston Drive
Redwood City CA 94063 / US
 [2019/22]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2019/22]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date17830099.219.07.2017
[2019/22]
WO2017AU00150
Priority number, dateUS201662363982P19.07.2016         Original published format: US 201662363982 P
[2019/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018014067
Date:25.01.2018
Language:EN
[2018/04]
Type: A1 Application with search report 
No.:EP3487522
Date:29.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 25.01.2018 takes the place of the publication of the European patent application.
[2019/22]
Search report(s)International search report - published on:AU25.01.2018
(Supplementary) European search report - dispatched on:EP27.02.2020
ClassificationIPC:A61K38/21, A61K39/395, C07K16/30, A61P39/00, A61K31/663, A61K39/00, C07K16/28, A61P35/02, A61K33/42, A61P35/00, C07K14/56
[2020/14]
CPC:
A61P39/00 (EP); C07K16/2803 (EP,US); A61K31/663 (EP);
A61K38/212 (EP,US); A61K39/39558 (EP); A61P35/00 (EP,US);
A61P35/02 (EP); C07K14/56 (EP); C07K16/2896 (EP,US);
A61K2039/505 (EP); A61K2039/507 (EP); C07K2317/41 (EP);
C07K2317/732 (EP); C07K2317/76 (EP); C07K2319/75 (EP) (-)
C-Set:
A61K39/39558, A61K2300/00 (EP)
Former IPC [2019/22]A61K38/21, A61K39/395, C07K16/30, A61P39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/22]
TitleGerman:ANTI-CD47-KOMBINATIONSTHERAPIE[2019/22]
English:ANTI-CD47 COMBINATION THERAPY[2019/22]
French:POLYTHÉRAPIE ANTI-CD47[2019/22]
Entry into regional phase19.02.2019National basic fee paid 
19.02.2019Search fee paid 
19.02.2019Designation fee(s) paid 
19.02.2019Examination fee paid 
Examination procedure19.02.2019Examination requested  [2019/22]
28.09.2020Amendment by applicant (claims and/or description)
13.05.2022Despatch of a communication from the examining division (Time limit: M04)
14.09.2022Reply to a communication from the examining division
Fees paidRenewal fee
25.07.2019Renewal fee patent year 03
23.07.2020Renewal fee patent year 04
26.07.2021Renewal fee patent year 05
27.07.2022Renewal fee patent year 06
20.07.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2014094122  (TRILLIUM THERAPEUTICS INC [CA]) [Y] 1-15* See example 4 *;
 [Y]US2016068612  (CLARKE ADAM [AU], et al) [Y] 1-15 * See § 130-132, examples, claims *
International search[Y]WO2011143624  (UNIV LELAND STANFORD JUNIOR [US], et al) [Y] 1-33 * See SEQ ID Nos: 1 and 2, [0007-8], [00102], Examples and Claims *;
 [Y]WO2013059885  (CEPHALON AUSTRALIA PTY LTD [AU], et al) [Y] 1-33* See SEQ ID Nos: 384-389, Examples and Claims *;
 [Y]WO2014144357  (MERCK PATENT GMBH [DE], et al) [Y] 1-33 * See SEQ ID Nos: 54, 56, 59, 60, 78, 82, 84, 86, 93 and 94, pp. 17, Examples 5, 8, 9 and Claims *;
 [Y]WO2014178820  (TEVA PHARMACEUTICALS AUSTRALIA PTY LTD [AU], et al) [Y] 1-33 * See SEQ ID Nos: 152, 156, 161, 165, 166, 167, 179, 180, 182, 184, 185, 188, 197, 198, 704, 706, 707, 708, 709, 710, 711, 720, 721, 722, 723, 739, 740, 741, and 742, Examples and Claims *;
 [Y]WO2015105995  (UNIV LELAND STANFORD JUNIOR [US]) [Y] 1-33 * See Examples and Claims *;
 [Y]WO2015138600  (UNIV LELAND STANFORD JUNIOR [US]) [Y] 1-33 * See [0086], [00125-7], [00136], [00142-00152] and Claims *;
 [Y]WO2016022971  (UNIV LELAND STANFORD JUNIOR [US]) [Y] 1-33 * See [0071], [0097-00107] and Claims *;
 [Y]WO2016065409  (TEVA PHARMACEUTICALS AUSTRALIA PTY LTD) [Y] 1-33 * See SEQ ID Nos: 48 and 81, Examples and Claims *;
 [Y]  - MCCRACKEN, M. et al., "Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD 47 ''Don't Eat Me'' Signals", Clin. Cancer. Res., (20150000), vol. 21, no. 16, pages 3597 - 601, XP055330326 [Y] 1-33 * See pp. 3597 and 3599 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-14-2520
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.